BOK Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

BOK Financial’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-16	Closed	-$292	–	1163
2024 Q1	$292	Buy	+16	New	+$396	﹤0.01%	1155

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BOK Financial's ACAD Position: Q2 2024 in Review

BOK Financial sold out of Acadia Pharmaceuticals (ACAD) in Q2 2024, closing a stake of 16 shares — an estimated $292 sold.

BOK Financial first reported a position in ACAD in Q1 2024 and held it in 1 quarter. The position peaked at $292 in Q1 2024. 264 funds tracked by Wall St. Rank hold ACAD as of Q2 2024.

BOK Financial reported no remaining Acadia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
BOK Financial sold 16 Acadia Pharmaceuticals shares in Q2 2024, an estimated $292.
BOK Financial first reported a position in Acadia Pharmaceuticals in Q1 2024 and held it in 1 quarter.
BOK Financial's Acadia Pharmaceuticals position peaked at $292 in Q1 2024.
264 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2024.

Based on BOK Financial's 13F filing for Q2 2024, filed 8 Aug 2024.